Yi-Xin Wang
Arete Therapeutics Inc.
7000 Shoreline Court
Suite 201
South San Francisco
USA
Name/email consistency: high
- Soluble epoxide hydrolase in atherosclerosis. Wang, Y.X., Ulu, A., Zhang, L.N., Hammock, B. Curr. Atheroscler. Rep (2010)
- A novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) - part I: pharmacological characterization. Wang, Y.X., Zhao, L., Nagashima, M., Vincelette, J., Sukovich, D., Li, W., Subramanyam, B., Yuan, S., Emayan, K., Islam, I., Hrvatin, P., Bryant, J., Light, D.R., Vergona, R., Morser, J., Buckman, B.O. Thromb. Haemost. (2007)
- A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis. Wang, Y.X., da Cunha, V., Vincelette, J., Zhao, L., Nagashima, M., Kawai, K., Yuan, S., Emayan, K., Islam, I., Hosoya, J., Sullivan, M.E., Dole, W.P., Morser, J., Buckman, B.O., Vergona, R. Thromb. Haemost. (2007)